EAM
RNAM

EFG Asset Management’s Avidity Biosciences RNAM Stock Holding History

EFG Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$6.5M Sell
149,149
-20,383
-12% -$824K 0.84% 26
2025
Q2 		$4.81M Buy
169,532
+14,112
+9% +$421K 0.68% 51
2025
Q1 		$4.59M Buy
155,420
+35,917
+30% +$1.12M 0.76% 32
2024
Q4 		$3.48M Buy
119,503
+58,198
+95% +$2.43M 0.47% 80
2024
Q3 		$2.81M Buy
61,305
+31,313
+104% +$1.36M 0.47% 82
2024
Q2 		$1.23M Buy
+29,992
New +$861K 0.21% 169

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EFG Asset Management's RNAM Position: Q3 2025 in Review

EFG Asset Management reduced its Avidity Biosciences (RNAM) stake by 12% in Q3 2025, selling an estimated $824K and leaving 149,149 shares worth $6.5M. The position accounts for 0.84% of the portfolio, ranked #26.

EFG Asset Management first reported a position in RNAM in Q2 2024 and has held it in 6 quarters since. 272 funds tracked by Wall St. Rank hold RNAM as of Q3 2025.

  • EFG Asset Management held 149,149 shares of Avidity Biosciences worth $6.5M as of Q3 2025.
  • EFG Asset Management sold 20,383 Avidity Biosciences shares in Q3 2025, an estimated $824K.
  • Avidity Biosciences made up 0.84% of EFG Asset Management's portfolio in Q3 2025, its #26 holding.
  • EFG Asset Management first reported a position in Avidity Biosciences in Q2 2024 and has held it in 6 quarters since.
  • 272 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.